What Eilean Therapeutics does

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022 and headquartered in Dover, Delaware, with a wholly-owned Australian subsidiary (Eilean Therapeutics AU Pty Ltd) used for first-in-human Phase 1 dosing via the Australian HREC/TGA CTN pathway. The company is developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, with the stated objective of overcoming the limitations of current oncology therapeutics. Its pipeline spans JAK2 V617F (ZE74-0282 for myelofibrosis), FLT3-mutated AML (lomonitinib), BCL2-driven CLL/AML (eiletoclax), menin-KMT2A AML (balamenib), MALT1 degradation for ulcerative colitis (TE205), brain-penetrant CDK2/CDK4, pan-EGFR, PTPN2/PTPN1 (acquired via Ness Therapeutics), c-MET, pan-KRAS, KRAS G12D, and BTK programs. Lomonitinib was selected for a new arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial and received FDA IND clearance in 2024.

The company's discovery engine is a proprietary hybrid AI/ML drug design platform that leverages Expert Systems Inc. technology and partner proprietary data to accelerate rational design, with demonstrated selectivity outcomes including >500-fold JAK2 V617F JH2 versus WT selectivity, picomolar JAK2 V617F potency, and >1000-fold PTPN2/PTPN1 selectivity over other phosphatases. The portfolio includes multiple modalities — selective kinase inhibitors, molecular degraders, covalent and reversible binders, and protein-protein interaction inhibitors — designed for combination potential.

Eilean is pre-revenue, with no commercialized products and pricing not publicly disclosed. The intended revenue model is eventual drug commercialization and licensing, supported by clinical development co-funding through partnerships such as the LLS Beat AML Master Clinical Trial. The company is co-founded by OrbiMed, Torrey Pines Investment, and Dr. John C. Byrd (Chairman of UC Department of Internal Medicine, serving as Interim Chief Medical Officer), with a full C-suite development team (CEO Iain Dukes, CSO Amy Burd, COO Nikolay Savchuk, CDO Brian Ledwith, Head of CMC Fraser Pickersgill) for a company of 11–50 employees.

Name

Eilean Therapeutics

Legal name

Eilean Therapeutics Inc.

Website

https://eileanther.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Eilean Therapeutics is a privately held, clinical-stage small molecule oncology drug discovery company founded in 2022, developing pan-variant therapies that target escape mutations and resistance mechanisms in hematologic malignancies and solid tumors, supported by a proprietary hybrid AI/ML drug design platform.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

Keywords

• Oncology drug discovery
• Small molecule therapeutics
• Kinase inhibitor development
• Hematologic cancer therapies
• Targeted cancer treatments

Headquarters

HQ city

Dover

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Eilean Therapeutics is a pre-revenue biopharmaceutical company focused on discovering and developing small molecule therapies. Revenue will be generated through eventual commercialization of drug candidates upon successful clinical development and regulatory approvals. The company develops proprietary therapeutics targeting genetic vulnerabilities in hematologic malignancies and solid tumors.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Eilean Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule targeted therapies for hematologic malignancies and solid tumors. Its pipeline includes selective kinase inhibitors, protein degraders, and immuno-oncology agents designed to overcome resistance mechanisms in cancers such as AML, CLL, NSCLC, and inflammatory bowel disease. The company leverages a proprietary hybrid AI/ML drug design platform to rationally design first-in-class and best-in-class oncology drug candidates.

Product overview

Eilean Therapeutics is a small molecule oncology drug discovery company developing a diversified pipeline of targeted cancer therapies. The company's portfolio includes both hematologic malignancy programs (ZE74-0282 for JAK2-driven myeloproliferative neoplasms, lomonitinib for FLT3-mutated AML, eiletoclax for BCL2-driven cancers, balamenib for menin-driven AML, MALT1 degrader for B-cell malignancies) and solid tumor programs (brain-penetrant CDK2/CDK4 inhibitors, pan-EGFR inhibitor, c-MET inhibitor, pan-KRAS molecular glue, KRAS G12D inhibitor). The company also acquired a PTPN2 inhibitor program for immuno-oncology. Programs span discovery through Phase 1 clinical stages, with several having received regulatory clearance for human trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Lomonitinib (ZE46-0134) Highly potent and selective pan-FLT3/IRAK4 inhibitor targeting clinically relevant FLT3 mutations including the gatekeeper mutation, as well as putative escape pathways in relapsed/refractory AML. FDA IND-cleared for U.S. Phase 1 trial.
• Eiletoclax (ZE50-0134) Highly potent and selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax, for treatment of AML and CLL. Phase 1 trial initiated in Australia.
• Balamenib (ZE63-0302) Selective best-in-class oral small molecule inhibitor of the menin-KMT2A interaction for treatment of AML, with improved safety profile including absence of QTc prolongation.
• ZE74-0282 Highly selective JAK2 V617F inhibitor targeting the JH2 pseudokinase domain of mutant JAK2, developed as a once-daily oral therapy for myeloproliferative neoplasms including myelofibrosis and polycythemia vera. Demonstrates >500-fold selectivity for mutant over wild-type JAK2.
• TE205 (MALT1 Degrader) First-in-class oral MALT1 degrader demonstrating in vivo efficacy as a disease-modifying therapy for ulcerative colitis and B-cell malignancies. Selectively degrades MALT1 to suppress NF-κB signaling and restore intestinal integrity.
• PTPN2 Inhibitor
• CDK2 Inhibitor Selective, brain-penetrant CDK2 inhibitor for treatment of CCNE1-amplified cancers and aggressive solid tumors. Demonstrates high selectivity for CDK2 over other cyclin-dependent kinases with broad therapeutic window.
• CDK4 Inhibitor
• Pan-EGFR Inhibitor (ZE77-0273) Reversible, brain- and lung-permeable pan-EGFR inhibitor demonstrating broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC) with high selectivity index versus wild-type EGFR.
• c-MET Inhibitor
• Pan-KRAS Molecular Glue
• KRAS G12D Inhibitor
• BTK Inhibitor

Quantifiable outcome

• >500-fold selectivity for JAK2 V617F JH2 versus WT JAK2 JH2 in cellular assays
• +4 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• The Leukemia & Lymphoma Society (LLS)coreStrategic or Co-development Partner · 11 June 2024Eilean Therapeutics joined The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial, a groundbreaking collaborative targeted treatment approach. Eilean's lomonitinib was selected for a new trial arm for patients with FLT3 mutated relapsed/refractory AML. Beat AML is among the first cancer clinical trials sponsored by a nonprofit, bringing together clinicians, cancer centers, pharmaceutical companies, and operational partners.
• Ness Therapeutics Inc (Ness)coreStrategic or Co-development Partner · 4 March 2024Eilean Therapeutics acquired Ness Therapeutics Inc in an all-equity transaction to obtain best-in-class PTPN2 inhibitors providing immuno-oncological therapy with improved safety and tolerability profile. Ness' lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding >1000-fold selectivity against all other phosphatases.
• Expert Systems Inc.coreTechnology or IntegrationEilean Therapeutics utilizes a proprietary hybrid AI platform of Expert Systems Inc., leveraging key partners' proprietary data, chem/bio tools, knowledge and expertise to choose highly valuable molecular mechanisms of pathology, rationally design, accelerate discovery and optimize development of best-in-class and first-in-class therapies.
• Mondego BiominorStrategic or Co-development PartnerEilean's PTPN2 inhibitor program is partnered with Mondego Bio, a Portuguese startup developing cancer immunotherapy treatments. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Syndax Pharmaceuticals: Develops revumenib (FDA-approved menin inhibitor) for KMT2A-rearranged AML — the lead competing asset to Eilean's balamenib in the menin-KMT2A space with established commercial validation.
• Disc Medicine: Clinical-stage small molecule company focused on hematologic diseases with multiple programs in early-stage trials — similar team size, capital profile, and hematology-focused pipeline breadth as Eilean.
• Geron Corporation: Clinical-stage hematology company developing telomerase inhibitor (Rytelo) for myeloid hematologic malignancies — comparable late-stage clinical profile in genetically-defined hematology indications.
• Mirati Therapeutics: Was a small molecule oncology company developing KRAS inhibitors (KRAZATI) acquired by Bristol Myers Squibb — directly comparable for Eilean's pan-KRAS molecular glue and KRAS G12D programs and demonstrates large-pharma M&A appetite for differentiated KRAS assets.
• Kura Oncology: Clinical-stage small molecule oncology company developing menin inhibitors (ziftomenib) for AML — directly comparable to Eilean's balamenib program. Both target genetically-defined AML populations and compete for similar clinical/partnering opportunities.
• Forma Therapeutics: Was a clinical-stage small molecule company focused on hematologic malignancies and rare cancers (acquired by Novo Nordisk for $1.1B) — direct comparable for Eilean's hematology pipeline and demonstrates M&A exit path.
• Rigel Pharmaceuticals: Small molecule hematology/oncology company with approved kinase inhibitors and pipeline targeting hematologic malignancies — comparable business model, therapeutic focus, and small-cap clinical-stage profile to Eilean.

Broad incumbents

• Blueprint Medicines: Established small molecule oncology company with approved kinase inhibitors (AYVAKIT) targeting hematologic malignancies and solid tumors — represents the scaled commercial endpoint for Eilean's kinase-inhibitor pipeline strategy.
• Incyte Corporation: Major hematology/oncology company with JAKAFI (ruxolitinib) — the incumbent JAK2 inhibitor against which Eilean's wild-type-sparing ZE74-0282 must differentiate for myelofibrosis/polycythemia vera market share.

Emerging players

• Foghorn Therapeutics: Clinical-stage biotech using a proprietary gene regulatory platform to develop small molecule oncology therapies — analogous platform-driven discovery model to Eilean's AI/ML approach with similar pipeline breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eilean-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eilean Therapeutics